La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
BioNTech Gestion
Gestion contrôle des critères 4/4
Le PDG BioNTech's est Ugur Sahin, nommé en Jan2008, a un mandat de 16.58 ans. La rémunération annuelle totale est € 3.06M, composée du salaire de 22.9% et des bonus 77.1%, y compris les actions et options de la société. détient directement 17.37% des actions de la société, d'une valeur de $ 3.52B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 4.4 ans.
Informations clés
Ugur Sahin
Directeur général
€3.1m
Rémunération totale
| Pourcentage du salaire du PDG | 22.9% |
| Durée du mandat du directeur général | 16.6yrs |
| Propriété du PDG | 17.4% |
| Durée moyenne d'occupation des postes de direction | 3.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.4yrs |
Mises à jour récentes de la gestion
Recent updates
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16
BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€504m |
| Mar 31 2024 | n/a | n/a | €113m |
| Dec 31 2023 | €3m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
| Sep 30 2019 | n/a | n/a | -€122m |
| Jun 30 2019 | n/a | n/a | -€116m |
| Mar 31 2019 | n/a | n/a | -€77m |
| Dec 31 2018 | €653k | €210k | -€48m |
Rémunération vs marché: La rémunération totale de Ugur ($USD 3.39M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: La rémunération de Ugur a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Ugur Sahin (59 yo)
16.6yrs
Titularisation
€3,056,000
Compensation
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 16.6yrs | €3.06m | 17.37% € 3.7b | |
| Co-Founder | 6.6yrs | €814.00k | 0.38% € 80.8m | |
| CFO & Member of Management Board | 3.1yrs | €1.32m | 0.00068% € 143.1k | |
| MD, COO & Member of Management Board | 10.6yrs | €821.00k | 0.32% € 66.8m | |
| Chief Strategy Officer | 4.6yrs | €1.41m | 0.0062% € 1.3m | |
| Chief Legal & Business Officer & Member of the Management Board | less than a year | €848.00k | pas de données | |
| Executive Officer | less than a year | €133.00k | 0.34% € 72.2m | |
| Senior Vice President of Corporate Development & Strategy | less than a year | pas de données | pas de données | |
| Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | pas de données | pas de données | |
| Senior Vice President of Operations | no data | pas de données | pas de données | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | pas de données | pas de données | |
| Senior Vice President of Global R&D Digital | no data | pas de données | pas de données |
3.8yrs
Durée moyenne de l'emploi
57yo
Âge moyen
Gestion expérimentée: L'équipe de direction de BNTX est considérée comme expérimentée (ancienneté moyenne 3.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Supervisory Board Member | 2.2yrs | €90.00k | 0.00017% € 35.8k | |
| Independent Deputy Chairman Supervisory Board | 6.6yrs | €114.00k | pas de données | |
| Independent Supervisory Board Member | 16.6yrs | €80.00k | pas de données | |
| Independent Supervisory Board Chairman | 16.6yrs | €226.00k | 0.14% € 29.4m | |
| Member of Supervisory Board | 1.3yrs | €46.00k | pas de données | |
| Supervisory Board Member | 2.2yrs | €105.00k | 0.00010% € 21.0k |
4.4yrs
Durée moyenne de l'emploi
58.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BNTX sont considérés comme expérimentés (ancienneté moyenne 4.4 ans).